OOIR: Observatory of International Research

Papers

(The H4-Index of ACS Medicinal Chemistry Letters is 30. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Psychiatric Treatments with Short-Duration Psychedelics and AI-Driven Behavioral Monitoring	163
Discovery of Tumor-Targeted 6-Methyl Substituted Pemetrexed and Related Antifolates with Selective Loss of RFC Transport	139
Issue Editorial Masthead	92
Issue Publication Information	74
Cancer-Cell-Selective Targeting by Arylcyclopropylamine–Vorinostat Conjugates	62
Clozapine as an E3 Ligand for PROTAC Technology	56
Tryptamines and Mental Health: Activating the 5-HT Receptor for Therapeutic Potential	53
Polybromo-1 Bromodomain Inhibitor Selectivity Is Mediated by a Unique Ligand-Binding Pocket	51
Novel PSMA-Targeting Radionuclide Peptidomimetics for Treating Prostate Cancer	48
Design and Synthesis of a Structurally Stabilized B-Chain Antagonist Targeting Relaxin Family Peptide Receptor 3 (RXFP3)	48
Novel Heterocyclic Pyrimidine Derivatives as GSK3α Inhibitors	46
Novel Tetrahydrobenzo[b]pyrazolo[3,4-e][1,4]diazepine Compounds as Oxytocin Receptor Agonists for Treating Autism Spectrum Disorders	44
In This Issue, Volume 14, Issue 5	43
Call for Papers: Fungal Pathogens – Life Cycle, Infection, Host Immunity and Drug Discovery	41
Novel Phosphorylpurinone Compounds for Treating Cancer	40
Methyl and Fluorine Effects in Novel Orally Bioavailable Keap1–Nrf2 PPI Inhibitor	39
Design and Characterization of 1,3-Dihydro-2H-benzo[d]azepin-2-ones as Rule-of-5 Compliant Bivalent BET Inhibitors	39
Emerging Techniques in Cancer Therapy: Precision Targeting for Improved Outcomes	38
Discovery of Pyridopyrazine Inverse Agonists Targeting G Protein-Coupled Receptor 6	37
Modulation of Cancer Networks through Protein Degradation, DNA Repair Inhibition, and Quantitative Interactomics	36
Discovery of Niclosamide Analogs with Potent Mitochondrial Uncoupling Activity and Reduced Mitochondrial Inhibition–Associated Toxicity	36
Multimodal Control of STAT6 Signaling through Small-Molecule Modulation and Targeted Degradation	33
Discovery of Orally Bioavailable FGFR2/FGFR3 Dual Inhibitors via Structure-Guided Scaffold Repurposing Approach	33
Structure–Activity Relationship and In Silico Evaluation of cis- and trans-PCPA-Derived Inhibitors of LSD1 and LSD2	33
Introducing the Potential Binding Interface between the TRAIL-Mimicking Peptide and DR5 via Alanine Scan	32

Application of Deuterated N,N-Dimethyltryptamine in the Potential Treatment of Psychiatric and Neurological Disorders	31
Discovery of Quinazolinone Derivatives as Potent PARP1 Inhibitors	31
Identification and Optimization of Small Molecule Pyrazolopyrimidine TLR7 Agonists for Applications in Immuno-oncology	31
Conformationally Restricted Analogues of α-Galactosylceramide as Adjuvant in COVID-19 Subunit Vaccine	30
Targeting the “Undruggable” Driver Protein, KRAS^G12D, as Potential Therapy in Prostate Cancer	30